The short term objectives of this K02 proposal are: 1) to expand the scope the applicant's active imaging genetic R01 by adding a high-throughput genome-wide epigenetic component;2) to actively seek additional training in the areas of statistical genetics and epigenetics;and 3) to establish new and enhance existing collaborations with prominent statistical and imaging genetics experts. The long-term objective of the K02 award is to bolster the applicant's scientific career and to further facilitate her growth into a prolific and highly successful independent investigator in the AD field. The applicant has developed an active research program focused on the imaging genetic biomarkers of AD. Her recently funded R01 award studies the associations between clinical, imaging and transcriptomic disease-associated traits in a prospective longitudinal cohort of cognitively normal and prodromal AD subjects. The objective of the science integral to this proposal is to expand the scope of the experiments to include newly acquired epigenetic data. The short-term scientific goals are to integrate epigenetics with the genomic, transcriptomic, clinical and imaging data from the parent R01 in order to elucidate the epigenetic effects on gene expression, brain atrophy, brain amyloidosis and disease risk. The long-term scientific goals of the R01 and K02 are to identify novel disease-associated pathways and therapeutic targets. To ensure the success of the proposed work, the applicant will be supported by a diverse group of distinguished collaborators with expertise in highly relevant fields and methods.

Public Health Relevance

The proposed research is relevant to public health as there is an urgent need for biomarkers capable of early and presymptomatic diagnosis and for discovery of critical disease-associated pathways. The proposed research is highly relevant to the mission of NIA because it will 1) identify and test key imaging and peripheral blood genetic biomarkers that when combined will help diagnose early AD and 2) critically inform AD drug development.

National Institute of Health (NIH)
Research Scientist Development Award - Research (K02)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Hsiao, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code